# Affinity Asset Advisors

> Affinity Asset Advisors is a VC fund backing Biotechnology and Health Care. See 21 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 21
- Last investment: Jul 2026
- Lead investor: 14%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/affinityassetadvisors
- Website: http://www.affinityadv.com

Affinity Asset Advisors is a healthcare-focused hedge fund with public and private investments. The company is a hedge fund manager based in New York that was founded in 2018.

## Contacts

5 contacts available for Affinity Asset Advisors. Shizune tracks 3 team members at Affinity Asset Advisors. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/affinity-asset-advisors?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 29% |
| Health Care | 5 | 24% |
| Therapeutics | 4 | 19% |
| Medical | 2 | 10% |
| Computer | 1 | 5% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 3 | 14% |
| Series A | 2 | 10% |
| Series B | 1 | 5% |
| Series C | 1 | 5% |
| Series D | 1 | 5% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 29% |
| Canada | 1 | 5% |
| Singapore | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Daniel Heller | Partner and Chief Investment Officer | 3 | https://shizune.co/investors/profile/daniel-heller-d065 |
| Michael Cho | Managing Partner and Portfolio Manager | 0 | — |
| Patrick Nosker | Partner and Director of Research | 0 | — |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Jasper Therapeutics | Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem celltransplant. | $132M | Post-IPO Equity | Jul 16, 2026 |  |
| Quince Therapeutics | Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M | Post-IPO Equity | May 18, 2026 |  |
| Climb Bio | Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline.Eliem Therapeutics develops and commercializes potentially“best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. | $110M | Post-IPO Equity | Apr 28, 2026 |  |
| Sol-Gel Technologies | Sol-Gel designs and delivers innovative dermatological drugs ranging from completely non-leachable to highly-controlled-release of unique formulations and compounds. | $33.1M | Post-IPO Equity | Mar 23, 2026 |  |
| Ovid Therapeutics | Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based onkey insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe. | $60M | Post-IPO Equity | Mar 17, 2026 |  |
| Korro Bio | Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in proteinstructure and function across multiple tissues.In 2018, | $85M | Post-IPO Equity | Mar 09, 2026 |  |
| MedinCell | MedinCell is an injectable slow-release drug specialist company. | $55.7M | Post-IPO Equity | Mar 05, 2026 |  |
| Sutro Biopharma | Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF.Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. | $110M | Post-IPO Equity | Feb 10, 2026 |  |
| Perspective Therapeutics | Perspective Therapeutics is dedicated to finding the best ways to deliver remedies to patients and their medical needs, and they believe in a targeted, individualized approach to cancer treatment. We design treatments that are given exactly where the doctor needs them. | $175M | Post-IPO Equity | Feb 02, 2026 |  |
| Odyssey Therapeutics | Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $213M | Series D | Sep 10, 2025 |  |

10 of 21 investments shown.

## Co-investors
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 6 deals together
- ADAR1 Capital Management — VC Fund, 5 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 5 deals together
- [Balyasny Asset Management](https://shizune.co/investors/profile/balyasny-asset-management) — VC Fund, 4 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 4 deals together
- [Lightspeed Venture Partners](https://shizune.co/investors/profile/lightspeed-venture-partners) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Affinity Asset Advisors invest in?

Affinity Asset Advisors invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series A stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Affinity Asset Advisors?

Public channels for Affinity Asset Advisors include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Affinity Asset Advisors?

The team at Affinity Asset Advisors includes Daniel Heller (Partner and Chief Investment Officer), Michael Cho (Managing Partner and Portfolio Manager) and Patrick Nosker (Partner and Director of Research). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co